Surgical Oncology And Breast Disease
Help Questions
USMLE Step 2 CK › Surgical Oncology And Breast Disease
A 46-year-old woman presents with a palpable breast mass. She has dense breasts on prior imaging and is worried that mammography will miss cancer. Exam shows a 2-cm firm mass; no skin changes. She has no contraindications to imaging. The clinician explains that for women ≥40 with a palpable mass, diagnostic mammography is first-line, often combined with targeted ultrasound; breast MRI is reserved for specific indications such as high-risk screening, problem-solving, or staging in selected cases, not as initial test for most palpable masses.
What is the most appropriate initial diagnostic test for this patient's breast mass?
Repeat clinical breast exam after next menstrual cycle before imaging
Therapeutic lumpectomy without imaging to avoid diagnostic delays
Breast MRI as the sole initial test due to dense breast tissue
Whole-body PET/CT to evaluate for occult primary and metastases
Diagnostic mammography with targeted ultrasound of the palpable region
Explanation
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest a palpable mass in a woman with dense breasts requiring initial evaluation, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending diagnostic mammography with targeted ultrasound as first-line for palpable masses in women ≥40. Choice B is incorrect because it represents misuse of MRI as initial test, which often arises from overestimating its role in routine diagnostics. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
A 38-year-old woman who is 24 weeks pregnant presents with a new left breast lump for 2 weeks. She denies fever or nipple discharge. She has no prior breast imaging. Exam shows a 2-cm firm mass without overlying erythema; no axillary nodes are palpable. She is concerned about fetal radiation exposure. The clinician explains that evaluation of a palpable mass in pregnancy begins with breast ultrasound, which is safe and can guide biopsy if suspicious; diagnostic mammography with abdominal shielding may be added if needed.
What is the most appropriate initial diagnostic test for this patient's breast mass?
Targeted breast ultrasound of the palpable area
Technetium bone scan to screen for skeletal metastases
Delay all imaging until after delivery unless severe pain develops
Breast MRI with gadolinium as the first-line pregnancy test
CT chest with contrast to evaluate for metastatic disease
Explanation
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest a palpable mass during pregnancy requiring safe evaluation, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending targeted ultrasound as the initial test in pregnancy to avoid fetal radiation exposure. Choice C is incorrect because it represents inappropriate use of contrast agents, which often arises from ignoring pregnancy-specific safety concerns. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
A 52-year-old woman presents with unilateral eczematous changes of the left nipple for 4 months. She reports itching and occasional serous discharge. Topical steroids provided minimal relief. She has no fevers. Exam shows erythema and scaling of the nipple-areolar complex with slight crusting; a subtle subareolar firmness is appreciated. No axillary nodes are palpable. Diagnostic mammography shows microcalcifications beneath the nipple. Punch biopsy of the nipple shows malignant cells within the epidermis consistent with Paget disease. The clinician explains that this finding is usually associated with underlying DCIS or invasive carcinoma and requires breast imaging and definitive surgical management.
Which of the following is the most likely diagnosis given the patient's presentation and test results?
Contact dermatitis requiring stronger topical corticosteroids only
Fibrocystic change requiring no imaging if symptoms are chronic
Paget disease of the breast associated with underlying ductal carcinoma
Inflammatory breast cancer without need for tissue diagnosis
Duct ectasia managed with warm compresses and reassurance
Explanation
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest Paget disease with underlying carcinoma confirmed by biopsy, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending evaluation for associated DCIS or invasive disease requiring surgical management. Choice B is incorrect because it represents undertreatment with topical therapy, which often arises from confusing malignant with benign dermatologic conditions. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
A 58-year-old woman is diagnosed with a 0.9-cm ductal carcinoma in situ (DCIS) detected on screening mammography as clustered microcalcifications. She has no palpable mass. Stereotactic core biopsy confirms DCIS, ER positive, with no invasion. Breast MRI shows no additional lesions. She prefers breast conservation. The surgeon explains that standard management is breast-conserving surgery (lumpectomy) with negative margins followed by whole-breast radiation to reduce local recurrence; sentinel lymph node biopsy is generally not required with lumpectomy for pure DCIS but may be considered with mastectomy.
Which treatment option is most aligned with current clinical guidelines for this condition?
Neoadjuvant chemotherapy to shrink DCIS before surgery
Routine axillary lymph node dissection at time of lumpectomy
Radical mastectomy with pectoralis removal to prevent recurrence
Observation only because DCIS cannot progress to invasive cancer
Lumpectomy with negative margins followed by whole-breast radiation therapy
Explanation
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest small, non-invasive DCIS suitable for breast conservation, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending lumpectomy with negative margins followed by radiation to reduce recurrence. Choice D is incorrect because it represents unnecessary nodal surgery, which often arises from overgeneralizing invasive cancer protocols to DCIS. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
A 57-year-old woman presents with back pain and fatigue 6 years after treatment of ER-positive breast cancer with lumpectomy, radiation, and 5 years of endocrine therapy. She reports new mid-thoracic pain worse at night. Exam shows mild tenderness over the thoracic spine but no neurologic deficits. Labs reveal elevated alkaline phosphatase and normal calcium. She has no breast mass on exam. Given concern for metastatic recurrence, the clinician explains that evaluation typically includes imaging for bone metastases and staging studies; management of metastatic ER-positive disease often includes systemic endocrine therapy with targeted agents, with local therapy for symptom control.
Which of the following is the most appropriate next step in management for this patient?
Reassure and treat as musculoskeletal strain without further workup
Start empiric antibiotics for presumed vertebral osteomyelitis
Obtain imaging for suspected bone metastases, such as bone scan or PET/CT
Schedule prophylactic mastectomy to prevent metastatic progression
Repeat screening mammography only, as it detects most recurrences
Explanation
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest possible bone metastases with elevated alkaline phosphatase years post-treatment, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending bone scan or PET/CT for symptomatic evaluation in suspected recurrence. Choice B is incorrect because it represents diagnostic omission, which often arises from attributing symptoms to benign causes without investigation. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
A 44-year-old woman presents with a palpable breast mass. She has a strong family history: mother with ovarian cancer at 49 and maternal aunt with breast cancer at 42. Exam reveals a 2-cm irregular mass; no skin changes. Diagnostic mammography and ultrasound are suspicious. Core biopsy confirms invasive ductal carcinoma. She asks about genetic testing and how it affects surgical planning. Current recommendations support genetic counseling/testing for patients with early-onset breast cancer and suggest that results may influence consideration of bilateral mastectomy and risk-reducing salpingo-oophorectomy in BRCA carriers.
Which of the following is the most appropriate next step in management for this patient?
Recommend observation because family history suggests benign disease
Avoid genetic testing because it does not change breast cancer treatment
Refer for genetic counseling and germline testing to guide surgical risk-reduction decisions
Order CA-125 screening only, then decide on breast surgery
Proceed directly to radical mastectomy regardless of genetic results
Explanation
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest early-onset breast cancer with strong family history warranting genetic evaluation, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending genetic counseling and testing to inform risk-reduction strategies like bilateral mastectomy in carriers. Choice B is incorrect because it represents underutilization of genetics, which often arises from underestimating its impact on surgical decisions. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
A 70-year-old woman presents with a new right breast mass. She has COPD and chronic kidney disease stage 3. Exam shows a 3-cm firm mass with skin tethering and palpable axillary nodes. Core biopsy confirms invasive ductal carcinoma, HER2 positive, ER negative. Echocardiogram shows normal LVEF. She asks about treatment sequencing. The oncologist explains that HER2-positive tumors often benefit from neoadjuvant chemotherapy plus HER2-targeted therapy to downstage disease and improve surgical options; surgery follows with appropriate axillary staging and radiation based on surgical approach.
Which treatment option is most aligned with current clinical guidelines for this condition?
Observation and repeat biopsy in 6 months to confirm receptor status
Neoadjuvant chemotherapy with HER2-targeted therapy followed by definitive breast surgery
Immediate mastectomy without systemic therapy because HER2 disease is localized
Radiation alone to the breast and axilla as definitive curative treatment
Tamoxifen monotherapy as primary treatment because surgery is high risk
Explanation
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest locally advanced HER2-positive breast cancer suitable for neoadjuvant therapy, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending neoadjuvant chemotherapy with HER2-targeted agents to downstage disease before surgery. Choice C is incorrect because it represents incorrect sequencing, which often arises from underestimating systemic therapy's role in HER2-positive disease. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
A 56-year-old woman is diagnosed with ER-positive, HER2-negative invasive ductal carcinoma after core biopsy. She is postmenopausal and plans for lumpectomy with sentinel node biopsy. She asks why receptor testing matters. The clinician explains that ER positivity predicts benefit from adjuvant endocrine therapy (e.g., aromatase inhibitor in postmenopausal women) to reduce recurrence; it is standard in guideline-based care. Chemotherapy decisions depend on stage, grade, nodal status, and genomic assays in selected cases.
Which of the following is most aligned with current clinical guidelines for this condition?
Defer all adjuvant therapy until routine surveillance imaging shows recurrence
Recommend antibiotics first to assess if the mass resolves
Plan adjuvant endocrine therapy after surgery due to ER-positive tumor biology
Use trastuzumab because ER positivity predicts HER2-targeted benefit
Avoid endocrine therapy because surgery alone cures all ER-positive cancers
Explanation
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest ER-positive invasive carcinoma in a postmenopausal woman planning surgery, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending adjuvant endocrine therapy post-surgery to reduce recurrence based on receptor status. Choice B is incorrect because it represents undertreatment, which often arises from misconceptions that surgery alone is curative regardless of biology. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
A 66-year-old woman presents with progressive right breast skin thickening and redness for 3 weeks. She was treated with oral antibiotics for presumed mastitis without improvement. She denies breastfeeding and has no fever. Exam shows diffuse erythema involving more than one-third of the breast with peau d’orange and a poorly defined underlying firmness; ipsilateral axillary nodes are palpable. Diagnostic mammography and ultrasound show skin thickening and an ill-defined mass. Core biopsy confirms invasive carcinoma with dermal lymphatic invasion. The team discusses that inflammatory breast cancer is aggressive and typically managed with neoadjuvant systemic therapy followed by mastectomy and radiation, not upfront lumpectomy.
Which of the following is the most likely diagnosis given the patient's presentation and test results?
Acute bacterial mastitis requiring broader-spectrum antibiotics and drainage
Paget disease limited to the nipple-areolar complex without invasion
Fibroadenoma with reactive skin changes from hormonal cycling
Fat necrosis after trauma requiring reassurance only
Inflammatory breast cancer requiring neoadjuvant therapy and multimodal treatment
Explanation
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest inflammatory breast cancer with failed antibiotic response and biopsy confirmation, which is key to determining the appropriate management step. The correct answer, choice A, is correct because it aligns with guidelines recommending neoadjuvant therapy followed by mastectomy and radiation for this aggressive subtype. Choice B is incorrect because it represents diagnostic delay, which often arises from misattributing symptoms to infection despite lack of improvement. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.
A 62-year-old woman presents with a palpable right breast mass and recent unintentional 6-kg weight loss. She went through menopause at 50 and never used hormone therapy. She has hypertension and type 2 diabetes. Exam reveals a 3.5-cm hard, irregular mass with nipple retraction and peau d’orange overlying skin; two right axillary nodes are enlarged. Diagnostic mammography and ultrasound show a suspicious mass and abnormal nodes. Core biopsy confirms invasive ductal carcinoma, triple-negative. Staging CT shows no distant metastases. She asks whether breast-conserving surgery is possible. The surgeon explains that lumpectomy requires negative margins and is typically followed by whole-breast radiation; mastectomy is an alternative. Neoadjuvant chemotherapy is often recommended for stage II–III triple-negative disease to downstage tumor and assess response.
Which treatment option is most aligned with current clinical guidelines for this condition?
Lumpectomy alone without radiation because margins can be negative
Tamoxifen therapy as primary treatment given high recurrence risk
Immediate radical mastectomy with routine removal of pectoralis muscles
Observation with imaging every 6 months because CT shows no metastases
Neoadjuvant chemotherapy followed by surgery with appropriate axillary staging
Explanation
This question tests USMLE Step 2 CK skills in surgical oncology and breast disease management, focusing on evidence-based clinical decision-making. Understanding breast cancer management involves recognizing appropriate diagnostic and treatment strategies based on patient presentation and current guidelines. In this scenario, the patient's clinical findings and test results suggest locally advanced triple-negative breast cancer without metastases, which is key to determining the appropriate management step. The correct answer, choice B, is correct because it aligns with guidelines recommending neoadjuvant chemotherapy for stage II–III triple-negative disease to downstage the tumor and assess response before surgery. Choice A is incorrect because it represents undertreatment by omitting radiation, which often arises from misconceptions about margin status eliminating recurrence risk. To effectively manage breast disease cases, students should stay updated on guidelines, understand risk stratification, and practice integrating clinical findings with management planning.